ARMD Presentation — Full Explanation with Feedback Notes

Your Feedback Score: 4/5 — SOLID. 1 Gap Filled (Tachyphylaxis)

Section 1 — Definition & Overview (Slides 1-3)

• Leading cause of irreversible legal blindness in developed countries (age ≥65)
• Affects ~3.5 million in the USA (2020); projected 5-9 million by 2050
• Two late forms: Geographic Atrophy (GA) = dry; Neovascular AMD (nAMD) = wet
• nAMD causes ~90% of severe vision loss despite being less common than GA
• WHO ranks AMD as the 3rd most common cause of global blindness after cataract and glaucoma

Section 2 — Anatomy of the Macula (Slide 4)

Section 3 — Epidemiology (Slides 5-7)

• Prevalence doubles each decade after age 50; >15% in Whites aged ≥80
• USA: Early AMD ~15.4 million; Late AMD ~2.1 million (NEI 2020)
• Nepal-specific data (a highlight of this presentation):
  • AMD causes 8.7% of total blindness in Nepal
  • 1 in 3 Nepalis aged ≥60 has some form of AMD (Thapa R et al., Clin Ophthalmol 2017; Bhaktapur district, n=1,860)
  • BEH hospital data included with sex distribution
  • 52.5% of AMD patients at KMCTH had VA 6/24-6/60; 15% had VA <3/60

Section 4 — Risk Factors (Slides 9-10)

• Advanced age (strongest overall), family history (3-4× risk), White race, female sex, hyperopia (+1D = 13% increased odds), light iris colour

• Cigarette smoking (2-4× risk - strongest modifiable factor; ~20% of cases in women)
• Systemic hypertension, high dietary fat/low omega-3, obesity/high BMI, low lutein/zeaxanthin, sedentary lifestyle

Section 5 — Genetics (Slide 11)

Section 6 — Pathogenesis (Slides 12-15)

Genetic susceptibility (CFH, ARMS2) + Environmental triggers → RPE dysfunction (↑lipofuscin/A2E, ↓phagocytosis) → Extracellular deposits in Bruch's (Basal Laminar Deposits → Drusen) → Complement activation + Oxidative stress + Inflammation → either GA (dry, late) or nAMD (wet, late)

• CFH normally inhibits the alternative pathway by cleaving C3b
• C3 convertase → C3a + C3b → C5 convertase → C5a + MAC (C5b-9)
• MAC deposition on RPE → cell lysis and photoreceptor death
• Drusen contain: vitronectin, complement C5b-9, C3d, CFH, immunoglobulins

• A2E (N-retinylidene-N-retinylethanolamine) is the principal toxic fluorophore in RPE lysosomes
• Inhibits lysosomal enzymes, activates complement, induces RPE apoptosis
• Detectable on FAF as hyper-autofluorescence
• Therapeutic target: ALK-001 (deuterated Vitamin A) in Phase 2/3 GO-STAR trial

• RPE hypoxia → HIF-1α → ↑VEGF-A mRNA (VEGF-A165 dominant isoform)
• VEGFR-2 (KDR/Flk-1) = main signalling receptor → endothelial proliferation + permeability
• Drug targets by receptor coverage: Pegaptanib (only VEGF-A165) → Ranibizumab/Bevacizumab (all VEGF-A) → Aflibercept (VEGF-A, VEGF-B, PlGF) → Faricimab (VEGF-A + Ang-2)

Section 7 — Drusen (Slides 16-17)

• Hard drusen (small, sharp edges - low risk)
• Soft drusen (large, indistinct - higher risk)
• Cuticular/basal laminar drusen
• Reticular pseudodrusen / SDD (above RPE - very high risk)

Section 8 — Types of MNV & Special Subtypes (Slides 18-23)

• Type 1 MNV - sub-RPE (occult CNV); often quiescent; associated with PCV
• Type 2 MNV - sub-retinal (classic CNV); leaks early on FFA
• Type 3 MNV (RAP) - intraretinal origin (deep capillary plexus); three stages

• Located ABOVE the RPE (unlike drusen which are sub-RPE)
• Appear yellow-white ~250 µm; best seen on NIR reflectance
• High-risk: linked to Type 3 MNV, GA progression
• Complement D localises here (unlike soft drusen) - distinct pathogenesis

• Branching inner-choroidal network + terminal aneurysmal polyps
• Now classified as pachychoroid aneurysmal Type 1 MNV
• More common in Asians (22-54% of nAMD) and Africans; female > male (5:1)
• Presents with serosanguineous PED + massive subretinal haemorrhage
• Up to 50% may resolve spontaneously

• Stage I = intraretinal neovascularisation (IRN); Stage II = subretinal (SRN); Stage III = retinal-choroidal anastomosis (RCA)
• 10-20% of nAMD in White patients; often bilateral and underdiagnosed

Section 9 — Classification (Slides 24-25)

• Normal (no features)
• Early AMD (small/medium drusen only)
• Intermediate AMD (at least 1 large druse ≥125 µm OR multiple medium drusen)
• Late AMD (GA or nAMD)

Section 10 — Clinical Features (Slides 26-32)

• Symptoms: Gradual central vision loss, Amsler grid changes, poor dark adaptation (earliest functional sign)
• Signs: Drusen, RPE pigmentary changes
• GA: Well-demarcated RPE loss; pericentral "horseshoe" pattern → concentric foveal sparing → eventual foveal involvement
• Rod dysfunction precedes visible photoreceptor loss by years

• Symptoms: Sudden central visual loss, metamorphopsia, central scotoma
• Signs: SRF, IRF, PED, subretinal haemorrhage, exudate, disciform scar
• Fellow eye risk: 10-12% per year develop CNV

• ≥4 disc diameters; haemoglobin → iron → free radical toxicity within 24-72 hours
• Urgent treatment needed within 7-14 days
• Management algorithm: small/extrafoveal → anti-VEGF alone; large/subfoveal → intravitreal tPA (100 µg) + C3F8 gas + anti-VEGF OR vitrectomy + subretinal tPA

1. Serous PED - dome-shaped, optically empty on OCT; treat if MNV notch present
2. Fibrovascular PED - irregular, heterogeneous OCT; anti-VEGF
3. Drusenoid PED - soft drusen confluence; AREDS2 + monitor
4. Haemorrhagic PED - urgent anti-VEGF ± subretinal tPA

• Mechanism: Large fibrovascular PED under tension → RPE splits and scrolls
• Risk factors: PED height >500 µm, PED width >1500 µm; commonly after anti-VEGF
• OCT: Sharp RPE discontinuity + hyperreflective scroll; FAF: hyper-AF at tear edge
• Management: Continue anti-VEGF - do NOT stop

• Fibrocellular replacement of regressed CNV; VA typically ≤6/60
• OCT: Hyperreflective dome-shaped mass; absent EZ; retinal atrophy
• Two phenotypes: fibrovascular (active - continue anti-VEGF) vs fibrocellular (quiescent)

Section 11 — Investigations & Imaging (Slides 33-37)

• SD-OCT: Mandatory for ALL AMD patients - assess fluid compartments, drusen, EZ integrity
• Dry AMD: add FAF (GA boundaries, junctional zones) + NIR (SDD)
• Wet AMD: add FFA (CNV type, trial eligibility) + ICGA (if PCV suspected) + OCTA

• GA = well-demarcated hypo-AF (no lipofuscin = no signal)
• Junctional zone patterns predict progression rate

• Rod Intercept (RI) measured by AdaptDx (MacuLogix)
• Normal RI: <6.5 min; Abnormal AMD: >6.5 min
• Delay precedes visible drusen by months to years (Owsley et al.)
• FARM study: Eyes with delayed RI at baseline were 2× more likely to develop AMD at 2 years

Section 12 — Differential Diagnosis (Slide 38)

Section 13 — Management of Dry AMD (Slides 39-40)

• Indicated for: Intermediate AMD (both eyes) OR advanced AMD/vision loss in one eye
• NOT indicated for early AMD or no drusen - no proven benefit

• 1 point per eye for large drusen (≥125 µm) OR any advanced AMD (max 4 points)
• Score ≥3 in at least one eye → start AREDS2 supplements

Section 14 — Management of Wet AMD (Slides 41-49)

Key point: Faricimab has 4 loading doses, all others have 3. This is the distinction to not mix up.

• Monthly (fixed): Best outcomes (CATT, ANCHOR, MARINA); high injection burden
• PRN (as needed): Less injections; risk of undertreatment
• T&E (Treat & Extend): Most widely used; extend by 2-week increments when dry; reduce when fluid recurs

Section 15 — Tachyphylaxis (Slide 49)

• Incidence: ~10-14% of patients on ranibizumab or bevacizumab
• Mechanism: The eye upregulates alternative angiogenic pathways (PDGF, Ang-2, HIF-1α) not blocked by the current drug - the CNV "finds a way around the blockade"
• Switch criteria: Persistent/recurrent fluid despite ≥3 consecutive injections of current agent
• Evidence: GEFAL, BRAMD, Lucas trials - switching improves anatomical outcomes in 50-60% of refractory cases
• Switch sequence: Bevacizumab → Ranibizumab → Aflibercept → Brolucizumab → Faricimab

Section 16 — Faricimab (Slides 56, 63)

• Ang-2 is elevated in wet AMD; it antagonises the Tie2 receptor on endothelial cells, destabilising vessels and increasing leakage/inflammation
• When you block VEGF-A alone, Ang-2 still destabilises vessels
• Faricimab blocks BOTH: VEGF-A blockade stops new vessel growth + Ang-2 blockade stabilises existing vessels via Tie2 activation
• This dual mechanism achieves more complete suppression → longer injection intervals (up to q16w)
• YOSEMITE (n=972) + LUCERNE (n=919): Non-inferior to aflibercept at 1 year (+5.5-6.7 letters); 45% of patients maintained q16w dosing at 2 years
• FDA approved January 2022 - ophthalmology's first dual-mechanism biologic

Section 17 — GA Treatments (Slide 58)

"These injections cannot bring back the vision you have already lost, and they cannot cure the disease. What they can do is slow down the rate at which the bare patch grows - so you keep your useful central vision for longer. Without treatment, the patch grows about 1.78 mm² every year. With treatment, we can reduce that by about 22-35%. It is not a cure, but it is meaningful - every month of useful central vision matters."

Section 18 — Extended-Duration Agents & New Approvals (Slides 55-67)

• Brolucizumab (Beovu): Approved 2020; q12w dosing; superior fluid control (HAWK/HARRIER). Concern: rare retinal vasculitis/occlusion
• Eylea HD (Aflibercept 8 mg): FDA approved Aug 2023; 4× molar dose; PULSAR trial showed non-inferiority with q12w/q16w intervals; 78% maintained q12w
• Port Delivery System (PDS/Susvimo): Implantable reservoir; ~88% refill-free at 6 months (ARCHWAY trial); FDA approved Oct 2021

Section 19 — Emerging Therapies (Slides 60-61, 68-69)

• Gene therapy: RGX-314 (subretinal AAV8), ADVM-022 (intravitreal), 4D-150 (dual VEGF-A+C blockade) - all in Phase II/III
• Photobiomodulation (PBM): LumiThera Valeda system; LIGHTSITE III - +4.1 letters vs +1.0 sham at 13 months
• Stem cell/RPE transplantation: hESC-RPE and iPSC-RPE patches; Phase 1/2 showing safety; Phase 3 not yet started
• Biosimilars: Aflibercept biosimilars (Opuviz, Pavblu, Ahzantive) FDA approved 2025; 40-60% cost reduction
• AI: Google DeepMind/Moorfields - AI matches retinal specialists in AMD referral; Home OCT (Notal Orbis) for remote monitoring

Section 20 — Prognosis & Natural History (Slide 70)

• Dry AMD: Slow; most maintain reading vision for years while fovea is spared
• GA growth rate: 1.78 mm²/year (range 0.53-5.6)
• Wet AMD untreated: 50% lose ≥3 lines at 2 years; 90% by 5 years
• Wet AMD treated: 30-40% gain ≥3 lines at 1 year; 40% maintain at 5 years
• Fellow eye: 10% annual risk; cumulative 30% at 5 years in high-risk eyes
• AMD rarely causes total blindness - peripheral vision is always preserved

Section 21 — Patient Education & Low Vision (Slides 71-73)

• Amsler grid: Test each eye separately at 30 cm; report new changes within 24 hours; limitation = up to 50% false-negatives
• ForeseeHome (PHP): Sensitivity 83%, Specificity 82%; FDA-cleared; 3×/week use
• Low vision aids: Magnifiers, CCTV, IMT (2.2-2.7× magnification for end-stage bilateral disease), eccentric viewing training
• Psychosocial: Depression in 40% of AMD patients - refer for counselling

Three Things to Review Tonight (from feedback):

1. The drug loading table - Faricimab has 4 loading doses, all others have 3
2. Tachyphylaxis - the word, 10-14% incidence, switch sequence (Bevacizumab → Ranibizumab → Aflibercept → Brolucizumab → Faricimab)
3. PCV vs RAP on ICGA - Branching network + polyps = PCV; hot spot near retinal vessel = RAP

AREDS2 Q1 - Perfect Answer Confirmed:

Retinal Layers Absent in the Macula (Fovea/Foveola)

At the Foveola (centre of the fovea, ~0.35 mm) — Most Layers Absent

Why Are These Layers Displaced?

"The fovea is a shallow depression within the retina where cells bodies of the ganglionic and INLs become dispersed peripherally, leaving primarily cone cells. Devoid of most conducting neurons as well as capillaries, the fovea allows light to fall directly on its cones with very little scatter." - Junqueira's Basic Histology, 17th ed.

"Except for the photoreceptor layer, most of the layers of the retina are markedly reduced or absent in this region." - Histology: A Text and Atlas (Ross), 9th ed.

Summary by Zone

Quick Exam Memory Aid

Foveal Avascular Zone (FAZ)

Definition

"A central area containing no blood vessels but surrounded by a continuous network of capillaries, located within the fovea but extends beyond the foveola. The exact diameter varies with age and in disease and its limits can be determined with accuracy only by fluorescein angiography (average 0.6 mm)." - Kanski's Clinical Ophthalmology, 10th ed.

Normal Dimensions

Why Does the FAZ Exist? (Anatomy)

1. Choriocapillaris - the fenestrated capillary layer of the choroid, which delivers oxygen and nutrients by diffusion through Bruch's membrane and the RPE
2. The avascular design is not a deficiency - it is purposeful. Retinal vessels would:
   • Cast shadows on the photoreceptors
   • Scatter and refract incoming light
   • Reduce the cone packing density possible at the fovea

Clinical Significance

1. Landmark for Laser Treatment

• Diabetic macular oedema (focal/grid laser)
• Extrafoveal CNV in AMD
• Central serous chorioretinopathy

2. Macular Ischaemia - FAZ Enlargement

3. OCTA - Non-Invasive FAZ Measurement

• Precise measurement of FAZ area, perimeter, and circularity index
• Separate visualisation of the superficial vs deep capillary plexus FAZ
• Monitoring FAZ enlargement over time in diabetic retinopathy grading
• The deep capillary plexus FAZ is often enlarged earlier than the superficial one in diabetic macular ischaemia

4. Surgical Safety Margin

5. Parafoveal Telangiectasia (MacTel Type 2)

6. Prognostic Marker

• FAZ area on OCTA is now used as a biomarker in diabetic retinopathy clinical trials
• A larger baseline FAZ predicts worse visual prognosis and poorer response to anti-VEGF in diabetic macular oedema
• FAZ irregularity index (how non-circular the FAZ is) correlates with severity of macular ischaemia

How the FAZ is Assessed

Quick Summary

The FAZ in Relation to AMD

1. In Dry AMD / Geographic Atrophy (GA)

The FAZ is the Last Thing GA Spares - Until It Doesn't

2. In Wet AMD / Neovascular AMD (nAMD)

CNV Location Relative to the FAZ is the Most Important Prognostic Factor

3. Why Subfoveal CNV Causes Acute Severe Vision Loss

• The neovascular membrane lifts the RPE and neurosensory retina off Bruch's membrane directly beneath the foveal cones
• Subretinal fluid (SRF) accumulates under the foveola - even 50-100 µm of fluid separating cones from the RPE causes immediate vision distortion (metamorphopsia) and blur
• Intraretinal fluid (IRF) within the foveal layers causes cystic changes that disrupt cone packing
• Subretinal haemorrhage into the FAZ zone is directly toxic to cones within 24-72 hours (haemoglobin → iron → free radical damage)
• Fibrovascular PED directly under the FAZ pushes the foveal cones upward, creating a PED detachment that distorts the visual image

4. Treatment Endpoint and the FAZ - "Fluid Under the Fovea"

• IRF touching the foveal centre = treat immediately; even small amounts cause vision loss
• SRF under the foveola = treat; though some studies (FLUID trial) suggest small amounts of SRF may be tolerable in T&E protocols
• Dry fovea (no fluid in FAZ zone) = extend interval (T&E protocol)

5. End-Stage nAMD - Disciform Scar Over the FAZ

• Cone photoreceptors overlying the scar are permanently destroyed
• The ellipsoid zone (EZ line) on OCT is absent centrally
• VA is typically ≤6/60; a dense central scotoma replaces the FAZ
• The patient loses reading vision, face recognition, and driving ability permanently
• Peripheral vision is preserved (the rest of the retina outside the macula is unaffected) - this is why AMD rarely causes total blindness

6. OCTA and the FAZ in AMD Monitoring

• Type 1 MNV (sub-RPE CNV): Abnormal flow signals beneath the RPE layer adjacent to the FAZ - often present for years before symptoms
• Type 2 MNV (subretinal CNV): Neovascular fronds visible above RPE, often extending into or through the FAZ
• Type 3 MNV / RAP: Intraretinal vessels originating from deep capillary plexus adjacent to the FAZ, with anastomosis eventually reaching the FAZ
• GA monitoring: OCTA shows choriocapillaris flow deficit at the FAZ margins, predicting where GA will spread next

Summary: The FAZ in AMD

Yes - Your Understanding is Correct

Layer-by-Layer Breakdown Across Macular Zones

The Key Histological Fact That Defines the Macula

"Histologically, it [the macula] shows more than one layer of ganglion cells, in contrast to the single ganglion cell layer of the peripheral retina." - Kanski's Clinical Ophthalmology, 10th ed.

"Over most of the retina, the ganglion cells are only a single layer of cells. At the macula, however, they are piled as many as eight deep, although they are absent over the fovea itself." - Histology: A Text and Atlas (Ross), 9th ed.

Visual Summary: Thickness Profile Across the Macula

Peripheral    Parafovea      Fovea rim     Foveola
retina        (macula)       (slopes)      (centre pit)
─────────────────────────────────────────────────────
10 thin    →  10 layers,  →  Layers        Only outer
layers        THICKER,       thinning,     retina
              GCL up to      inner         remains
              8 layers       displacing    (cones + ONL
              deep           laterally     + RPE)

• The macula is the thickest region of the retina outside the optic disc
• The fovea is a depression/pit (thinner than surrounding macula)
• The foveola at the bottom of the pit is the thinnest point of the entire retina

Why This Matters Clinically in AMD

• In AMD, when people say "macular degeneration affects the macula," they mean all of this thick, multi-layered, cone-rich region
• But the functional impact is most devastating when the disease reaches the foveola - the thinned, inner-layer-free cone-only zone at the centre
• That is why GA "spares the fovea" for so long - the pericentral macula (parafovea, with all its layers) degenerates first, while the structurally distinct foveola resists longest

Why Blue/Grey Iris = Modest Increased AMD Risk

The Core Principle: Iris Colour = Proxy for Ocular Melanin Content

• Brown iris = high melanin content
• Blue/grey iris = low melanin content (the blue colour is actually a structural/Tyndall scattering effect from a melanin-poor stroma, not from blue pigment)

Where Melanin Matters in the Eye (and Why)

1. RPE Melanosomes

• Absorb stray and scattered light - prevents photons from bouncing back and damaging photoreceptors a second time
• Quench reactive oxygen species (ROS) - melanin acts as a free radical scavenger; without it, photo-oxidative damage accumulates in the RPE
• Protect against phototoxicity - especially short-wavelength (blue) light, which is the most energetic and damaging portion of the visible spectrum

"The dense RPE pigment serves to absorb stray light." - Kanski's Clinical Ophthalmology, 10th ed.

2. Choroidal Melanocytes

• Less light absorption within the choroid
• More light back-scatter reaching the RPE from behind
• Greater cumulative phototoxic load on the RPE over a lifetime

The Mechanistic Chain Linking Blue Iris → AMD

Blue/grey iris
    ↓
Low melanin in iris stroma → Low melanin in uveal tract (choroid + RPE)
    ↓
Less light absorption in choroid → More back-scattered photons hitting RPE
Less RPE melanin → Less ROS quenching per photon absorbed
    ↓
Greater cumulative oxidative stress on RPE over decades
    ↓
↑ Lipofuscin (A2E) accumulation in RPE lysosomes
↑ Oxidative damage to Bruch's membrane
↑ Complement activation
    ↓
Accelerated drusen formation → Earlier/more severe AMD

Why Short-Wavelength (Blue) Light is the Key Culprit

• It carries the most energy of all visible wavelengths (E = hc/λ - shorter wavelength = higher energy)
• It is specifically absorbed by A2E (the toxic bis-retinoid in RPE lipofuscin), which then generates singlet oxygen and ROS
• The RPE of lightly pigmented eyes has less melanin to intercept and neutralise these photons before they reach A2E

Why the Association is Only "Modest"

1. Confounding with race: Blue eyes predominantly occur in White/European populations, who already have higher AMD risk from genetic factors (CFH Y402H, ARMS2 variants). It is difficult to separate the iris colour effect from the underlying genetic susceptibility of that population.
2. RPE melanin is not perfectly correlated with iris colour: RPE melanin content varies somewhat independently of iris colour, especially with age - RPE melanin decreases with ageing in everyone regardless of iris colour, which may dilute the difference.
3. Melanin is dual-natured: Young melanin is photoprotective. But aged/oxidised melanin (particularly in the RPE) can actually generate ROS rather than quench them - so the relationship is not simply "more melanin = always better." This complexity weakens the epidemiological signal.
4. Other risk factors dominate: Smoking (2-4× risk), CFH genetics, age, and diet have far larger effect sizes than iris colour. The iris colour effect gets diluted in multivariate models.

Clinical Relevance in AMD Context

• This is why UV-protective sunglasses are recommended in AMD prevention guidelines - even if the evidence is described as "uncertain" (from your presentation), the rationale is sound: reducing phototoxic load on the RPE, especially in lightly pigmented eyes
• It also explains part of the racial disparity in AMD prevalence: White populations (predominantly lighter irides, lower total ocular melanin) have higher AMD rates than African Americans (predominantly darker irides, higher melanin)
• It connects to the A2E/lipofuscin pathway in AMD pathogenesis: A2E accumulation is driven by photo-oxidative stress, and less melanin = more unchecked blue-light-driven A2E generation

Basal Laminar Deposits (BLamD) in AMD

First - The Crucial Terminology Distinction

1. Basement membrane of RPE ← innermost
2. Inner collagenous layer
3. Elastic fibre layer
4. Outer collagenous layer
5. Basement membrane of choriocapillaris ← outermost

The Three Types of Sub-RPE Deposits

"Basal laminar deposit [is] a layer that accumulates between the RPE and the RPE basement membrane (the inner layer of Bruch membrane) in AMD. Basal linear deposit is a distinct finding consisting of membranous debris laid down between the RPE basement membrane and the inner collagenous layer of Bruch membrane that may progress focally to form drusen." - Kanski's Clinical Ophthalmology, 10th ed.

Basal Laminar Deposit (BLamD) - In Detail

Location (Precise)

RPE cell body
    ↓ ← BLamD sits HERE (between cell and its own basement membrane)
RPE basement membrane (= innermost layer of Bruch's)
    ↓ ← BLinD and drusen sit HERE
Inner collagenous layer of Bruch's
Elastic fibre layer
Outer collagenous layer
Choriocapillaris basement membrane
Choriocapillaris

Composition

• Wide-spaced collagen (periodicity ~100 nm on electron microscopy - characteristic)
• Fibronectin
• Laminin
• Abnormal basement membrane material secreted by dysfunctional RPE cells

How It Forms

Key Features

• Seen on electron microscopy (not visible on light microscopy or clinical imaging easily)
• Present in virtually all eyes over 50 years to some degree - so it is part of normal ageing as well as AMD
• In AMD, it is thicker and more abnormal in composition
• It is diffuse (spreads under the entire RPE) rather than focal like drusen
• On OCT, BLamD corresponds to the recently described finding of "outer retinal corrugations" - an undulating hyper-reflective layer beneath the RPE band

Clinical Significance in AMD

1. Barrier to nutrition: BLamD thickens the space between the RPE cell and its nutrient supply (choriocapillaris), impairing oxygen/glucose diffusion to the RPE
2. Impairs RPE adhesion: Normal RPE adhesion to Bruch's membrane depends on direct cell-basement membrane contact. BLamD physically separates them, predisposing to RPE detachment
3. Promotes drusen formation: BLamD disrupts normal RPE function, leading to increased secretion of BLinD material which then forms drusen
4. Complement activation: Components within BLamD trigger the complement cascade, driving the AMD inflammatory cycle
5. Precedes visible drusen: BLamD is often the earliest histological change detectable in AMD eyes, appearing before drusen are visible clinically

Basal Linear Deposit (BLinD) - Why It Matters More for Drusen

• Sits in the same sub-RPE-basement-membrane space as drusen
• When BLinD accumulates focally and mounds up, it creates what we clinically call a soft druse
• BLinD contains membrane fragments and lipid-rich material derived from partial degradation of photoreceptor outer segments that the RPE could not fully process
• The lipid in BLinD is derived from RPE lysosomes - it is essentially undigested outer segment material

Simple Memory Diagram

AMD deposit hierarchy (inner → outer relative to RPE):

[RPE cell]
    ↑
BLamD (between cell body and its own basement membrane)
    = Wide-spaced collagen; diffuse; earliest change
[RPE BASEMENT MEMBRANE] ← this is the inner layer of Bruch's
    ↑
BLinD (between RPE basement membrane and inner collagenous layer)
    = Membranous/lipid debris; focal accumulation
    ↓
Focal mounding of BLinD = SOFT DRUSEN (clinically visible)
[INNER COLLAGENOUS LAYER OF BRUCH'S]

On OCT in AMD

Summary